Teleflex to Present at Annual Meeting of the Association for Vascular Access (AVA)

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, announces that its technology will be the subject of symposiums and scientific presentations at the upcoming annual meeting of the Association for Vascular Access (AVA). Teleflex will also host AVA’s first-ever vascular access cadaver lab at the conference.

AVA 2014 will be held September 7-10 at the Gaylord National Resort and Convention Center, in National Harbor, MD.

The cadaver lab and several of the Teleflex symposiums and poster presentations include products from the ARROW® Brand portfolio. The portfolio includes vascular access devices such as antimicrobial and antithrombogenic PICCs and CVCs; the ARROW® VPS G4™ Vascular Positioning System®; and the new ARROW® EZ-IO® Needle + Stabilizer Kit. These products assist healthcare facilities in striving to achieve a goal of zero complications in vascular care by providing protection against catheter infection, thrombosis, occlusion, and malposition.

Teleflex will be at Booth 221 in Prince George’s Exhibition Hall E during the conference. At its booth, the company will focus special attention on its Chlorag+ard® Technology. This includes the ARROW® JACC with Chlorag+ard® Technology, the world’s only antimicrobial and antithrombogenic CVC, and the ARROW® PICC with Chlorag+ard® Technology, the world’s only antimicrobial and antithrombogenic PICC.

The cadaver lab will provide a unique hands-on opportunity for participants to practice vascular-access techniques as well as receive an in-depth review of associated anatomy on cadaveric specimens. It will be held Monday, September 8 from 7-9 p.m. in Potomac D on the convention center’s second level.

Other presentations include:

• Showcase – “You Can’t Afford Not to Understand Affordable Care” showcase with speaker Leslie Schultz, AN, PhD, CPHQ. 3:30 p.m., Monday, September 8, in Potomac 1-2.
• Dinner Symposium – “Chlorag+ard® Technology: Reducing a Triad of Associated Complications”, Kamna Giare-Patel, MS, AN, and Rebekah Limato, BS, ART. Monday, September 8, 7 p.m. in Potomac C on the second level.
• Breakfast Symposium – “Preserving Vascular Real Estate: Location is Important for the Renal Patient.” The speaker is Peter Wayne, MD. 7 a.m. Tuesday, September 9 in Potomac C on the second level.

The following are among 9 poster presentations at AVA evaluating technology from Teleflex:

• “Catheter technologies: Is eluting technology or non-eluting technology more effective in preventing thrombus accumulation?” by Kamna Giare-Patel, MS, et al. This study evaluated the effectiveness of three types of peripherally inserted central venous catheters (PICCs) as compared to uncoated PICCs, in a clinically simulated ovine model.

• “Are antibiotic-resistant ‘superbugs’ a real challenge to antimicrobial central venous catheter performance?” by Nisha Gupta, PhD, et al. The research compared the in vitro effectiveness of three antimicrobial CVCs against gram-positive and gram-negative “superbugs”.
• “Are PICCs with eluting technology more effective against antibiotic-resistant bacteria than non-eluting technology?” by Nisha Gupta, PhD, et al. The authors compared the antimicrobial effectiveness of three different types of PICCs against six antibiotic-resistant superbugs.
• “Can PICC technologies prevent catheter colonization by CLABSI-causing pathogens?” by Nisha Gupta, PhD, et al. Researchers compared the antimicrobial effectiveness of three different types of PICCs against 12 common pathogens responsible for causing central line-associated bloodstream infections (CLABSIs).

The posters will be displayed on Monday, September 8 from 8 a.m. to 5 p.m.; Tuesday, September 9 from 8 a.m. to 5 p.m.; and Wednesday, September 10 from 7 to 11:30 a.m. Authors will be available to answer questions about their posters on Monday, Sept. 8 from 8 to 9 a.m. and Tuesday, September 9 from 8 to 9 a.m.

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 11,500 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, Arrow, Chlorag+ard, EZ-IO, Vascular Positioning System and VPS G4 are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

© 2014 Teleflex Incorporated. All rights reserved. MC-000536

Teleflex IncorporatedJake Elguicze, 610-948-2836Treasurer and Vice President, Investor Relations